The abstract is read at the publisher; the summary is JClub's.
In the FIELD randomized trial, fenofibrate caused an acute eGFR drop of -9.05 ml/min/1.73 m2, while worsening total GFR slope by -1.54 ml/min/1.73 m2 per annum.
- Why it matters: Composite kidney endpoints can mix surrogate components that may not align with measured kidney function, especially when treatments trigger early eGFR changes through non-glomerular mechanisms.
- What they did: Adults were randomized to fenofibrate or placebo; total slope used a repeated-measures two-slope linear mixed model, chronic slope started at month four, and a three-year sensitivity analysis plus washout subgroup analyses were performed.
- The result: Fenofibrate improved chronic slope by 0.61 ml/min/1.73 m2 per annum (95% CI 0.50 to 0.71) but increased the composite kidney endpoint risk (hazard ratio 1.48, 95% CI 1.16 to 1.89), with washout analyses showing benefit on total slope.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.